Kestra Medical Technologies, Ltd.
In the published model solve dated 2026-Q2, anchored at $23.48, Kestra Medical Technologies, Ltd. (KMTS) is priced for today's economics sustained for ~19.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
The counterintuitive fact is that Kestra is taking share in a market long treated as a single-player franchise: ASSURE prescriptions rose 58% year over year to 5,462 in fiscal Q3 2026, and revenue grew 63% to $24.6 million. The company is not yet profitable. The net loss widened to $34.2 million from $21.8 million, and at about 11x revenue the price implies the business eventually reaches a roughly 16% operating margin and grows near its self-funding ceiling for about 17 years. Gross margin ex
Is KMTS overvalued? See what's priced in →
95 institutional managers reported holding KMTS in 13F filings for the quarter ended 2026-03-31. 15 opened new positions that quarter. Held by T. Rowe Price, FMR (Fidelity), BlackRock, among others. On the short side, 2.9M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at KMTS over the trailing three years: 2025: 1 buy totaling $289k; 2026: 1 buy totaling $200k. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
KMTS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2025-12-12 | +6.9% | +3.1% |
| 2026-03-18 | +1.6% | +5.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
KMTS's latest 8-K filings: 2026-07-14 (items 1.01, 1.02, 2.02, 2.03, 9.01); 2026-03-17 (items 2.02, 9.01); 2025-12-11 (items 2.02, 9.01); 2025-12-04 (items 1.01, 9.01); 2025-12-01 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.